Figure 5.
Inhibition of BCR prevents STAT5 activation in ABC-DLBCL. (A) Representative images of STAT5A immunofluorescence (left) and quantification for nuclei detection (right) after treatment with 20 nM AZD5153, 10 nM acalabrutinib, or a combination. n = 3. (B) TR-FRET detection of phos-STAT5 with stimulation by 0.1 ng/mL IFNα or 1 ng/mL IFNβ. n = 6 (C) Cell viability scoring (0-200) and (D) Cas3/7 activity across multiple doses of both drugs in TMD8 and TMD8-CD79B WT cell lines. n = 6. € PAX5 and STAT5A immunofluorescence quantification for nuclei detection comparing TMD8 (Mut) and TMD8-CD79B WT cell lines. Error bars represent SEM. ∗, #, and ## denote P < .05 for comparison of the control, acalabrutinib, and AZD5153, respectively.

Inhibition of BCR prevents STAT5 activation in ABC-DLBCL. (A) Representative images of STAT5A immunofluorescence (left) and quantification for nuclei detection (right) after treatment with 20 nM AZD5153, 10 nM acalabrutinib, or a combination. n = 3. (B) TR-FRET detection of phos-STAT5 with stimulation by 0.1 ng/mL IFNα or 1 ng/mL IFNβ. n = 6 (C) Cell viability scoring (0-200) and (D) Cas3/7 activity across multiple doses of both drugs in TMD8 and TMD8-CD79B WT cell lines. n = 6. € PAX5 and STAT5A immunofluorescence quantification for nuclei detection comparing TMD8 (Mut) and TMD8-CD79B WT cell lines. Error bars represent SEM. ∗, #, and ## denote P < .05 for comparison of the control, acalabrutinib, and AZD5153, respectively.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal